The QualityStocks Daily Wednesday, April 13th, 2022

Today's Top 3 Investment Newsletters

SmallCapRelations(HWAL) $1.0500 +191.67%

OTCtipReporter(KLDO) $0.3011 +75.06%

QualityStocks(HCMC) $0.0003 +50.00%

The QualityStocks Daily Stock List

Antares Pharma (ATRS)

MarketClub Analysis, MarketBeat, Real Pennies, StockMarketWatch,, Wall Street Resources, The Street, StockOodles, Hit and Run Candle Sticks, QualityStocks, Wealth Insider Alert, BUYINS.NET, StreetAuthority Daily, DrStockPick, CRWEWallStreet, CRWEPicks, CRWEFinance, ChartPoppers, BestOtc, Barchart, Clutch Investments, Investopedia, Jason Bond, AllPennyStocks, PennyOmega, Whisper from Wall Street, PennyToBuck, Rick Saddler, StockHotTips, StreetInsider, The Motley Fool, Trades Of The Day and Money Morning reported earlier on Antares Pharma (ATRS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Antares Pharma Inc. (NASDAQ: ATRS) (FRA: MJC) is a specialty pharmaceutical firm that is engaged in the development and commercialization of pharmaceutical technologies and products that address unmet needs.

The firm has its headquarters in Ewing, New Jersey and was incorporated in February 1979. It operates in the healthcare sector, under the biotech and pharma sub-industry. The firm has partnership arrangements and strategic alliances with pharmaceutical companies like AMAG, Teva, Idorsia and Pfizer.

The company is focused on developing, manufacturing and commercializing new therapies using its drug delivery systems. This is in addition to carrying out research and development with transdermal gel products.

The enterprise’s products include sublingual tablets developed for nocturia treatment dubbed NOCDURNA for adults who wake up at least twice a night to urinate; an injection for adults with serious recalcitrant psoriasis, children with polyarticular juvenile idiopathic arthritis and grown-ups with severe active rheumatoid arthritis dubbed OTREXUP OTREXUP; an injection developed for acute treatment of cluster and migraine headaches in adults dubbed Sumatriptan; an injection indicated for the treatment of osteoporosis in men at increased risk of fracture and postmenopausal women called Teriparatide; and an injection for testosterone replacement therapy termed XYOSTED. In addition to this, the enterprise develops disposable pen injectors for osteoporosis and diabetes; device/drug products for endocrinology and urologic oncology and QuickShot auto injectors. These needle-free injector systems are sold in different countries.

The company recently appointed a new Senior VP who has a lot of experience in marketing and operations at large pharmaceutical firms. This move will enhance the strong growth trajectory of the company’s proprietary portfolio and bring in more growth opportunities for the business.

Antares Pharma (ATRS), closed Wednesday's trading session at $5.58, up 49.1979%, on 117,269,862 volume. The average volume for the last 3 months is 117.27M and the stock's 52-week low/high is $3.11/$5.59.

Frequency Therapeutics (FREQ)

StreetInsider, MarketBeat, Trades Of The Day, InvestorPlace, The Street, The Online Investor, Schaeffer's and QualityStocks reported earlier on Frequency Therapeutics (FREQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Frequency Therapeutics Inc. (NASDAQ: FREQ) is a clinical-stage biopharmaceutical firm that is focused on using the human body’s biology to reverse damage or repair damage caused by various degenerative ailments.

The firm has its headquarters in Lexington, Massachusetts and was incorporated in 2014, on November 13th by Will J. McLean, Christopher Loose, David L. Lucchino and Robert S. Langer. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm serves consumers in the United States and has two companies in its corporate family.

The company is party to collaboration and licensing agreements with Cambridge Enterprises Ltd, the Scripps Research Institute, the Massachusetts Institute of Technology, Mass General Brigham, and Massachusetts Eye and Ear. In addition to this, it is also party to a license and collaboration agreement with Astellas Pharma Inc., which entails developing and commercializing FX322.

The enterprise’s product pipeline comprises of a formulation dubbed FX322, which is undergoing a phase 2 clinical trial evaluating its effectiveness in treating the underlying cause of sensorineural hearing loss. In addition to this, the enterprise is also involved in the development of treatments for patients with degenerative conditions like multiple sclerosis and diseases of the bone, skin, gastrointestinal tract and muscle.

The success of the company’s FX322 formulation, which has shown improvements in hearing over extended periods of time, may not only benefit patients with sensorineural hearing loss but also encourage more investments into the company, which will have a positive influence on its growth.

Frequency Therapeutics (FREQ), closed Wednesday's trading session at $1.66, up 22.963%, on 1,448,483 volume. The average volume for the last 3 months is 1.448M and the stock's 52-week low/high is $1.22/$12.19.

Hallador Energy (HNRG)

TradersPro, Zacks, SmarTrend Newsletters, Wall Street Resources, QualityStocks, MarketBeat, Market Intelligence Center Alert, Trading Concepts, StreetInsider, InvestorPlace and Daily Market Beat reported earlier on Hallador Energy (HNRG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hallador Energy Company (NASDAQ: HNRG) (FRA: H7H) is a coal mining firm that is focused on the production of steam coal for the electricity and power generation industry.

The firm has its headquarters in Terre Haute, Indiana and was incorporated in 1951 by David C. Hardie. It serves consumers in the United States.

The company’s operating business segments include two Oaktown underground mines which are found in southwest Indiana, known as Oaktown 1 Mine and Oaktown 2 Mine. It sells most of its coal to big coal-fired power plants in Indiana. The company mainly operates through its Sunrise Coal subsidiary.

The enterprise’s projects include Bulldog Mine, Carlisle mine, Oaktown 1 Mine, Oaktown 2 mine and the Ace in the Hole mine which is situated roughly 40 miles northeast of the Carlisle mine. The Bulldog mine controls more than 35 tons of coal reserves.

It develops more than 10 million tons of coal every year and has more than 40 million tons of the Indiana coal Vi sea. The enterprise also has more than 69 million controlled tons in Lawrence and Indiana county and Knox county, Illinois. In addition to this, it owns a transport facility on the Ohio River dubbed the Summit Terminal.

The company recently reported its first half financial results for this year which show improvements in contracted sales as well as an increase in shipments. It is focused on expanding its portfolio to include renewable energy, which will play a big role in the company’s evolution. The move will also bring in more investors into the firm, which will have a positive influence on the company’s growth.

Hallador Energy (HNRG), closed Wednesday's trading session at $5.04, up 25.062%, on 7,557,919 volume. The average volume for the last 3 months is 7.525M and the stock's 52-week low/high is $1.80/$5.30.

Healthier Choices Management (HCMC)

MarketBeat and QualityStocks reported earlier on Healthier Choices Management (HCMC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Healthier Choices Management Corp. (OTC: HCMC) is a holding firm that is focused on the provision of vaporizers, e-liquids and related products.

The firm has its headquarters in Hollywood, Florida and was incorporated in 1985 by Jeffrey Elliott Holman. Prior to its name change, the firm was known as Vapor Corp. It operates as part of the tobacco manufacturing industry and has ten companies in its corporate family. The firm serves consumers in the United States.

The company’s objective is to offer consumers healthier daily choices with respect to nutrition and other lifestyle alternatives. It operates through the vapor and the grocery segment. The former segment is focused on the provision of vaporizers, e-liquids and other products. On the other hand, the latter segment providers natural household items, health and beauty products, frozen foods, dairy products, baked goods, deli, meat and seafood, packaged groceries, vitamins and supplements, bulk foods and fresh produce.

The enterprise operates a natural and organic grocery store, Ada’s Natural Market, via Healthy Choice Markets Inc., its wholly owned subsidiary. It also operates Paradise Health and Nutrition with stores that provide fresh produce and other products, through its Healthy Choice Markets 2 LLC subsidiary. The enterprise also markets its Q-Cup technology, which is based off of a small quartz cup dubbed the Q-Cup. Consumers can buy this cup when it’s already filled by a 3rd party or fill it themselves with CBD or marijuana concentrate. In addition to this, the enterprise sells supplements and vitamins.

The company’s latest financial results show that its gross profit increased by 7% while its net loss reduced by almost 14% in the second quarter of 2021. The company is focused on implementing its growth initiatives, which include building a business model that supports its sustainable and long term growth.

Healthier Choices Management (HCMC), closed Wednesday's trading session at $0.0003, up 50%, on 2,169,183,103 volume. The average volume for the last 3 months is 2.168B and the stock's 52-week low/high is $0.00005/$0.0035.

Planet Green Holdings (PLAG)

StockMarketWatch, MarketClub Analysis, QualityStocks, TopPennyStockMovers, StreetInsider, Schaeffer's, PoliticsAndMyPortfolio, MarketBeat and BUYINS.NET reported earlier on Planet Green Holdings (PLAG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Planet Green Holdings Corp. (NYSE American: PLAG) is a diversified technology and consumer products firm that is focused on growing, manufacturing and distributing green tea, black tea and Cyan brick tea.

The firm has its headquarters in Flushing, New York and was incorporated in 1986, on February 4th by Si Chen. Prior to its name change in September 2018, the firm was known as American Lorain Corporation. It serves consumers around the globe, with a focus on China and North America.

The company operates through the Shanghai Xunyang and Fast Approach, Lucky Sky Planet Green Holdings Company Ltd, Planet Green Holdings Corporation, Planet Green Holdings Corporation BVI, Jiayi Technologies Co. Ltd, and Xianning Bozhuang divisions. It is focused on leveraging and exploring advanced technology to improve and expand its family of holdings.

The enterprise’s products include red tea, dark tea, green tea, white and blue porcelain tea, Qin Chu Cang Gong, Chinese zodiac, Shu Xing Cang Gong, brick tea, YiPin Chun Qiu and Zhen Pin Cheng Jian. It is also involved in researching, developing and manufacturing chemical products like ethanol fuel, formaldehyde, clean fuel, urea formaldehyde adhesive, fuel additives and methylal. This is in addition to operating an online demand-side platform which enables consumers of digital advertising inventory to manage more than one advertisement exchange and data exchange via one interface.

The company recently entered into an agreement with Shandong Yunchu Supply Chain Co. Ltd. This will help generate more shareholder value, extend the company’s consumer reach and bring in more investors into the firm, which will have a positive impact on the company’s growth.

Planet Green Holdings (PLAG), closed Wednesday's trading session at $1.04, up 26.7983%, on 2,377,153 volume. The average volume for the last 3 months is 2.346M and the stock's 52-week low/high is $0.7001/$2.40.

Genenta Science (GNTA)

Stockpalooza, OTCPicks, CoolPennyStocks, StockEgg, Standout Stocks, HotOTC, Penny Invest, BullRally, MadPennyStocks, PennyTrader Publisher, QualityStocks, PennyStockVille, OTCReporter, Penny Performers, PennyInvest, Stock Stars, StockRich,, AddictivePennyStocks, Wise Alerts,, TooNiceStocks, Epic Stock Picks,,, Penny Stock Finder,,, Penny Stock Rumble,,, Actual Gains, WiseAlerts,,, Stock Rich, Stock Preacher, Beacon Equity Research, Breaking Bulls, PennystockBullreport, Fast Moving Stocks, StocksGoneWild, Today's Financial News, StockHideout and EpicVIP Group reported earlier on Genenta Science (GNTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Genenta Science S.P.A. (NASDAQ: GNTA) (FRA: KSF) is a clinical-stage biotechnology firm that is focused on developing hematopoietic stem cell gene therapies for treating solid tumors.

The firm has its headquarters in Milan, Italy and was incorporated in 2014, on July 24th by Bernhard Gentner, Luigi Naldini and Pierluigi Paracchi. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is focused on developing lentivirus-based cell and gene therapies in cancer. It utilizes gene-based cytokine delivery to activate the immune system in the tumor. Its proprietary platform comprises of dual control achieved at the post-transcriptional and transcriptional level. These make sure that the therapies are released in the tumor. The company is present in the international markets but also operates locally.

The enterprise’s product pipeline comprises of a candidate dubbed Temferon, which carries an interferon-alpha payload and helps counteract growth of cancer while rebuilding the immune system. This candidate is undergoing phase I/IIa clinical trials evaluating its effectiveness when used to treat glioblastoma multiforme in individuals with unmethylated MGMT gene promoter. It also develops Temferon and many more immune-gene therapy programs for use in the treatment of intra-hepatic cholangiocarcinoma, locally advanced hepatocellular carcinoma and other solid tumor indications.

The company is focused on developing new medications, advancing its Temferon candidate and finding new applications for the candidate. This will bring in additional revenue into the firm and help create shareholder value, which will bolster its growth.

Genenta Science (GNTA), closed Wednesday's trading session at $6.44, up 5.4873%, on 810 volume. The average volume for the last 3 months is 810 and the stock's 52-week low/high is $5.11/$13.13.

Lyra Therapeutics (LYRA)

StreetInsider, MarketClub Analysis and BUYINS.NET reported earlier on Lyra Therapeutics (LYRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lyra Therapeutics Inc. (NASDAQ: LYRA) is a therapeutics firm that is engaged in developing and commercializing new delivery and drug solutions for the treatment of throat, nose and ear infections.

The firm has its headquarters in Watertown, Massachusetts and was incorporated in November 2005 by Robert S. Langer, George M. Whitesides and Carmichael S. Roberts. Prior to its name change in July 2018, the firm was known as 480 Biomedical Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers around the globe.

The company uses its technology platform, XTreo, to deliver medications to the diseased tissue which isn’t directly accessible with conventional approaches, for a prolonged period with one administration.

The enterprise’s product pipeline comprises of a bio-resorbable polymeric matrix dubbed LYR-220, which has been developed for chronic rhinosinusitis patients who have or don’t have basal polyps. The formulation targets patients with recurrent symptoms despite surgery. It also develops an anti-inflammatory implantable drug matrix known as LYR-210, which is based on the XTreo platform and targets patients who are surgically naive. These matrices can be administered in an in-office, non-invasive procedure and are intended for the localized delivery of medications, targeting tissues in the ENT passages as well as other affected tissue.

The firm recently announced its latest financial results, with its CEO noting that the firm remained focused on advancing its clinical programs and expanding its target addressable market, which will be good for its revenues and growth.

Lyra Therapeutics (LYRA), closed Wednesday's trading session at $6.24, up 0.807754%, on 391,843 volume. The average volume for the last 3 months is 391,211 and the stock's 52-week low/high is $3.30/$11.90.

Kraken Robotics (KRKNF)

QualityStocks, Trades Of The Day, Trading Concepts, MarketBeat, InvestorPlace and Daily Trade Alert reported earlier on Kraken Robotics (KRKNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kraken Robotics Inc. (OTCQB: KRKNF) (CVE: PNG) (FRA: 2KQ) is a marine technology firm that is focused on designing, manufacturing and selling software-centric batteries, sensors and underwater robotic systems for unmanned underwater vehicles for commercial and military applications.

The firm has its headquarters in Mount Pearl, Canada and was incorporated in 2008, on May 14th. Prior to its name change, the firm was known as Kraken Solar Inc. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm has seven companies in its corporate family and primarily serves consumers in North America.

The company operates through the Power, Sensors and Platforms segments. The power segment comprises of sub-sea equipment like thrusters, drives and batteries. On the other hand, the sensors and platforms segment is focused on services for marine laser and sonar scanner sensor equipment and marine vehicle platforms. It has operations in the United States, Canada and Europe.

The enterprise’s products include an underwater laser imaging system dubbed SeaVision; and, a configurable miniature interferometric synthetic aperture sonar known as AquaPix. It also offers a hovering autonomous underwater vehicle known as Thunderfish; a towed underwater vehicle for high resolution seabed mapping and high speed operation dubbed Katfish; and a removable data storage module known as DataPod for marine applications.

The firm was recently awarded a million dollar contract by a defense industry customer, which brings in significant revenues and opens the firm up to more growth and investment opportunities. This will also help create shareholder value.

Kraken Robotics (KRKNF), closed Wednesday's trading session at $0.36741, off by 0.312025%, on 116,804 volume. The average volume for the last 3 months is 116,804 and the stock's 52-week low/high is $0.24575/$0.58.

Longboard Pharmaceuticals (LBPH)

MarketBeat and BUYINS.NET reported earlier on Longboard Pharmaceuticals (LBPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Longboard Pharmaceuticals Inc. (NASDAQ: LBPH) is a clinical-stage biopharmaceutical firm that is engaged in the development of transformative medications for neurological ailments.

The firm has its headquarters in La Jolla, California and was incorporated in 2020, on January 3rd. Prior to its name change in October 2020, the firm was known as Arena Neuroscience Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers across the globe.

The company is focused on the advancement of promising investigational therapies for rare neurological indications. It specializes in centrally acting product formulations which have been designed to be highly selective for specific GPCRs (G protein-coupled receptors).

The enterprise’s product pipeline comprises of its pre-clinical product candidates, LP143 and LP659. LP659 is a centrally acting S1P receptor modulator in investigational studies for central nervous system neuro-inflammatory illnesses. LP143 is a centrally acting full CB2 agonist in investigational studies for neurdegenerative illnesses linked to neuroinflammation caused by microglial activation. Its other candidates include an oral, centrally acting 5-HT2c superagonist (5-hydroxytrptamine 2c receptor subtype) dubbed LP352, which is undergoing a phase Ib/IIa clinical trial evaluating its effectiveness in treating seizures linked with epileptic and developmental encephalopathies, including Lennox-Gastaut syndrome and Dravet syndrome.

The company recently appointed a new chief medical officer who has decades of experience across various areas of healthcare. This appointment will positively influence the advancement of the company’s pipeline and help address the unmet needs of patients with neurological indications.

Longboard Pharmaceuticals (LBPH), closed Wednesday's trading session at $5.25, up 1.6201%, on 1,266 volume. The average volume for the last 3 months is 1,266 and the stock's 52-week low/high is $3.90/$18.50.

Kaleido Biosciences (KLDO)

MarketBeat, StockProfessors, StockMarketWatch, BUYINS.NET, StreetInsider, MarketClub Analysis, Club Penny Stocks Network, WallstreetsHotteststocks, Wallstreetbuzz, Top Pros' Top Picks, PennyStockShark, Free Insider Alerts and Blaque Capital Stocks reported earlier on Kaleido Biosciences (KLDO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kaleido Biosciences Inc. (NASDAQ: KLDO) is a clinical-stage healthcare firm that is focused on the development of new microbiome metabolic therapies.

The firm has its headquarters in Lexington, Massachusetts and was incorporated in 2015, on January 27th by Noubar B. Afeyan and Geoffrey von Maltzahn. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves patients in the United States.

The company is party to collaboration agreements with Janssen, the Washington University and the Institute Gustave Roussy. It is focused on leveraging the microbiome organ to improve health in humans and treat various indications. The company is rapidly and cost-effectively advancing a pipeline of microbiome formulations with the potential to address various illnesses and disorders with unmet patient needs.

The enterprise’s product portfolio is made up of its product candidates, which are all MMTs (Microbiome Metabolic Therapies) that have been designed to modulate the metabolic profile and output of microbiomes. They include a formulation dubbed KB174, developed to treat hepatic encephalopathy; KB295 for the treatment of ulcerative colitis; KB195 developed to treat patients with urea cycle disorder; and the KB109 formulation, for the treatment of coronavirus infections. It also develops programs for the treatment of inflammatory bowel diseases, immuno-oncology, cardio-metabolic syndrome, atherosclerotic cardiovascular disease, chronic kidney disease and multi-drug resistant infection.

The firm remains focused on maximizing shareholder value and addressing the needs of patients with various indications, which will positively influence its growth as well as its revenues.

Kaleido Biosciences (KLDO), closed Wednesday's trading session at $0.3011, up 75.0581%, on 189,994,283 volume. The average volume for the last 3 months is 188.803M and the stock's 52-week low/high is $0.1467/$9.47.

Healthcare Triangle (HCTI)

PennyStocks24, Epic Stock Picks, Wolf of Penny Stocks, QualityStocks, Orbit Stocks, Planet Penny Stocks, SecretStockPromo, StockOnion, Buzz Stocks, Pumps and Dumps, Mina Mar Marketing Group, PennyStockPlayers, Fast Money Alerts, Penny Stock Beats, MyBestStockAlerts, EpicVIP Group, Broad Street, OTPicks, Penny Pick Finders, Penny Stock Circle, Penny Stock General, 1-2-3 Stock Alerts, PennyStockClub, PennyStockProphet, PremiereStockAlerts, SmallCapVoice, Stock Shock and Awe, Stock Twiter,, Stocks That Move, The Stock Scout and Penny Stock Pros reported earlier on Healthcare Triangle (HCTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Healthcare Triangle Inc. (NASDAQ: HCTI) (FRA: 4MR) is a healthcare information technology firm that is focused on the development of data science, cloud services, professional and managed services solutions.

The firm has its headquarters in Pleasanton, California and was incorporated in 2019, on October 29th. It operates as part of the health information services industry, under the healthcare sector. The firm serves consumers around the globe.

The enterprise offers various software, platforms, solutions and services which enable organizations to deliver precision medicine, personalized healthcare, respond to evidence, partnered research and development, development and efficacy and improve digital transformation. Its software platforms include a software-as-a-service solution dubbed Readabl.AI, which uses machine learning and public cloud artificial intelligence to extract healthcare information from narrative reports, faxes and documents. It also offers a cloud-based analytics and data science platform known as DataEz, for the data science and data analytics requirements of healthcare and life sciences/pharmaceutical provider organizations. The firm also provides an enterprise multi-cloud transformation and management platform dubbed CloudEz, which allows consumers to manage their cloud infrastructure across public, hybrid and private cloud infrastructures. In addition to this, it provides healthcare IT services and cloud IT services. It mainly serves medical device manufacturers, biotechnology firms, pharmaceutical and life science companies, healthcare insurance firms and healthcare delivery organizations.

The company recently acquired Devcool Inc. It intends to use this acquisition to expand its addressable market opportunities in the healthcare provider space, which will be good for its revenues and positively influence its growth.

Healthcare Triangle (HCTI), closed Wednesday's trading session at $1.1779, up 1.5519%, on 4,564 volume. The average volume for the last 3 months is 4,563 and the stock's 52-week low/high is $0.8102/$4.35.

Freeport-McMoRan (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, StreetInsider, Trades Of The Day, TopStockAnalysts, Money Morning, Investopedia, Daily Trade Alert, Louis Navellier, VectorVest, Zacks,, Trading Markets, ProfitableTrading, The Growth Stock Wire, Daily Wealth, The Wealth Report, TheStockAdvisors, All about trends, Wall Street Elite, StreetAlerts, Top Pros' Top Picks, Streetwise Reports, Leeb's Market Forecast, The Online Investor, TradingMarkets, Market FN, Dividend Opportunities, Market Report, TheStockAdvisor, StockTwits, InvestmentHouse, Investor Guide, Investors Alley, Investment House, Trading Concepts, Wealth Insider Alert, The Best Newsletters, Options Trader Elite, Money and Markets, Market Intelligence Center Alert, InvestorGuide, Wyatt Investment Research, AnotherWinningTrade, Darwin Investing Network, Bourbon and Bayonets, Energy and Capital, Buttonwood Research, Wealth Daily, Trade of the Week, The Motley Fool, Investing Signal, MarketWatch, Investor Update, Profit Confidential, Market Authority, Wall Street Daily, Super Stock Investor, Street Insider, Trading Tips, Cabot Wealth, TradingAuthority Daily, Wealthpire Inc., Stock Research Newsletter, FNNO Newsletters, InvestorsUnderground, WStreet Market Commentary, CNBC Breaking News, Daily Markets, Uncommon Wisdom, Dynamic Wealth Report, FeedBlitz and Weekly Wizards reported earlier on Freeport-McMoRan (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Goldman Sachs, a leading investment bank, warned in a recently released report that copper was slowly headed in the direction of a stockout. Barely a month ago, the metal breached the $5 mark for each pound ($11,000 for a ton). However, the price rally has since toned down, and copper futures are trading at approximately $4.7 per pound in New York.

In February this year, Goldman sounded the alarm and warned that a major supply shortage is likely to hit the copper market before the year ends. At that time, existing stocks amounted to approximately 200,000 tons, which could hardly meet the consumption volumes needed for three days.

The report released by Goldman Sachs last week pointed out that the world was entering unprecedented territory. This is because for the last decade copper supplies usually rose in March, but this time around, a decline in stocks was registered. The investment bank thinks this is an ominous sign for what lies ahead, and it is heavily bullish about what is to come later in the year with regard to the price of copper.

Previously, the bank had estimated that the global copper shortfall this year would be in the region of 374,000 tons. Its recent report has now doubled this figure in addition to making an upward adjustment to the expected deficits over the coming years.

In order for the copper market to balance, the investment bank believes that prices must rise significantly so that the supply of copper scrap can be stepped up. At the same time, the higher prices could also help to suppress the ballooning demand and thereby trigger a balance between the existing copper supplies and the demand for this metal.

The report points out that in spite of the tight supply of copper this year, price increases haven’t been that significant. This is good for investors because they have ample opportunity to get into the market and ride along when the more dramatic price increases manifest in the months to come.

It should be noted that the transition to green energy and the push to make the switch to electric vehicles have combined to increase the demand for the so-called “energy metals,” including copper, nickel and lithium. These sectors are only just getting started, and there is limited chance that the demand for copper and other needed metals will wane any time soon.

When Goldman Sachs adjusts upwards its predictions of the price of copper over the next quarter, six months, and 18 months, one is compelled to pay attention since all pointers suggest the price will trend upwards. If this prediction plays out, major copper extractors such as Freeport-McMoRan (NYSE: FCX) are likely to give their shareholders great value for the money they invested in the firm.

Freeport-McMoRan (FCX), closed Wednesday's trading session at $49.43, up 3.302%, on 11,976,508 volume. The average volume for the last 3 months is 11.699M and the stock's 52-week low/high is $30.02/$51.99.

The QualityStocks Company Corner

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, hit a critical mineral “trifecta” this month, making commercial shipments of uranium, vanadium and advanced rare earth materials — all in a single week. According to the announcement, the company shipped natural uranium concentrates (“U308”) to the Metropolis Works uranium conversion facility in Metropolis, Illinois;  vanadium pentoxide (“V205”) to the Bear Metallurgical Company in Butler, Pennsylvania; and high-purity mixed rare earth element (“REE”) carbonate to the Neo Performance Materials facility in Estonia. “I believe the week of April 4, 2022, will go down as one of the most important weeks in company history,” said Energy Fuels CEO and president Mark Chalmers in the press release. “This week, our vision of Energy Fuels as 'America's Critical Mineral and Clean Energy Hub' tangibly advanced, as our White Mesa Mill in Utah sent three shipments of advanced materials containing a total of 15 critical elements, including the rare earth elements cerium, praseodymium, neodymium, samarium, europium, gadolinium, dysprosium, terbium, holmium, yttrium, erbium, thulium, ytterbium, and lutetium, along with uranium and vanadium, to downstream processing facilities. We sent a shipment of high-purity rare earth carbonate containing 32%–34% NdPr to Silmet in Estonia, where it will be refined and processed into various advanced materials for use in permanent magnets used in electric vehicle motors and wind generation, batteries, electronics, defense applications, and other technologies. We sent a shipment of uranium concentrates to ConverDyn in Illinois for sale to U.S. nuclear utilities for the production of carbon-free nuclear energy, and further adding to Energy Fuels' industry-leading finished U.S.-origin uranium inventory. And we sent another truckload of vanadium to Bear Met in Pennsylvania for conversion into ferrovanadium for use in high-strength steel and other advanced and specialty alloys. I could not be more proud of what our team is doing at the White Mesa Mill on rare earths.” To view the full press release, visit

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $10.82, up 8.0919%, on 7,612,920 volume. The average volume for the last 3 months is 7.547M and the stock's 52-week low/high is $4.32/$11.39.

Recent News


The QualityStocks Daily Newsletter would like to spotlight GreenBox POS (NASDAQ: GBOX).

  • On March 31, GreenBox POS released the financial results for the three months (“Q4 FY 2021”) and full year (“FY2021”) ended December 31, 2021
  • Company achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020
  • The Q4 FY2021 results build on Q3 2021 figures in which the company reported year-over-year growth in both transaction volume and revenues
  • The financial figures were accompanied by a corporate update and expected prospects for 2022.

On Thursday, March 31, at 4.30 PM Eastern, investors, stakeholders, and the general public heard about the progress that GreenBox POS (NASDAQ: GBOX), an emerging FinTech company leveraging blockchain technology to offer cutting-edge, customized payment solutions, made in the three months ended December 31, 2021 (“Q4 FY2021”) as well as throughout fiscal year 2021 (“FY2021”). GreenBox achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020. Processing volume for 2021 increased nearly tenfold to approximately $2.0 billion, from $202 million in 2020 ( GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has completed the System and Organization Controls (“SOC”) 2 Type 2 certification audit. The audit, which started in November 2021, focused on controls relevant to the security trust services category. According to the announcement, SOC 2 Compliance is a recognized auditing standard developed by the American Institute of Certified Public Accountants (“AICPA”) that evaluates a service organization's systems and determines if specified controls meet relevant trust services categories. Considered the gold standard for establishing trust with customers, the audit also measures the effectiveness of those controls over a specified period of time. “GreenBox customers rely on our customized payment-solutions software as the lifeline for their businesses,” said Greenbox CEO Fredi Nisan in the press release. “This requires the trust and integrity of our security, controls and risk management processes as well as strict adherence to compliance. By completing the SOC 2 type 2 certification, not only do we align ourselves with the industry standards followed by world class organizations, but given our strong growth trajectory, it is indicative of our commitment to protecting both our internal and external constituents while building trust with rigorous control processes and prudent risk management.” To view the full press release, visit

GreenBox POS (NASDAQ: GBOX) is an emerging financial technology company leveraging proprietary security and token technology to build customized payment solutions for business. The company’s mission is to build compliant, cutting-edge blockchain ledger tokenized solutions for the diverse, evolving and dynamic global market.

GreenBox applications enable an end-to-end suite of turnkey financial products which offer improved fraud detection and better handling efficiency of large-scale commercial payment processing volumes for its merchant clients globally. The company’s proprietary blockchain and smart contract token technologies create seamless payment processing using digital encryption keys.

GreenBox is a unified platform providing scalability for businesses to accept payments, transact, send, settle and convert in a single versatile ecosystem. GreenBox operates a private and proprietary blockchain-based payment platform that offers distinct advantages when compared to traditional payment technologies, including greater security and data privacy, as well as enhanced identity theft protection and quick settlement.

As the settlement engine for financial transactions, GreenBox’s blockchain technology is a distributed ledger that uses digitally encrypted keys to verify, secure and record details of each transaction conducted within GreenBox’s private ecosystem. The speed and security of the platform allows GreenBox to log immense volumes of immutable transactional records in real time for Tier-1 partners around the world.

In November 2021, GreenBox announced the closing of a previously announced $100 million convertible note financing. The company plans to use proceeds for acquisitions, a planned stablecoin spin-off, and additional working capital toward the company’s future growth. The initial conversion price equals a more than 80 percent premium to the market price of the company’s common stock on October 29, 2021, and values the enterprise at more than $700 million upon conversion.

Brands & Solutions

The company offers multiple solutions and brands under the GreenBox label. The other brands that are nested under the GreenBox POS label include coyni, ChargeSavvy, QuickCard, Transact Europe [didn’t yet close] and Northeast Merchant Systems. Each of these brands play a large role in allowing GreenBox to accel in customizing payment solutions across different verticals and industries.

Payment Solutions

The GreenBox platform offers blockchain secure, robust payment processing solutions for both individual consumers and businesses. The company combines the power and security of blockchain with bank-level tools necessary to both settle transactions and monitor cash flows. Customers can transfer cryptocurrencies like USDC, Ethereum or Bitcoin from external decentralized crypto wallets to their GreenBox wallets. They can also exchange those tokens from their GreenBox wallets to any supported coin. Customers can easily offload in USDC to a debit card or a multitude of gift cards.

White Label Solutions

The company’s white label platform allows it to partner with firms seeking blockchain-based tools to manage merchant relationships. White label partners can monitor cash flows, as well as run reports on merchant transactions, chargebacks, agent and affiliate commissions and more. Partners can access the platform through their partner portal to manage business relationships with full visibility. The platform’s cutting-edge technology saves partners time and simplifies their payment processing. It ensures compliance with automated Know Your Customer and Know Your Bank services and allows customers to set up automated payouts.

coyni Stablecoin

The company is planning soon to launch its own stablecoin, coyni (CYN). coyni is equivalent to the value of the U.S. dollar on a one-to-one ratio. Stablecoin allows for instantaneous transactions with blockchain security just like other cryptocurrency tokens, but without the price volatility of traditional cryptocurrencies. The CYN token is expected to make possible features like digital dollar accounts, cross border payments, international payment processing and other payment solutions. As a smart contract technology, coyni will offer instant settlement using the GreenBox blockchain ledger in any location and currency – crypto or fiat – all at lower fees and in a tokenized secure ecosystem.

Market Overview

A Mordor Intelligence report put the transaction value of the global digital payments market at $5.44 trillion in 2020 and projects the market to be worth $11.29 trillion by 2026. That represents a CAGR of 11.21 percent during the period of 2021-2026.

The report notes that the global COVID-19 pandemic and its impact on e-commerce is likely to encourage strengthened international cooperation and further development of policies for online purchasing and supply. The report states, “The pandemic has made it clear that e-commerce can be an important tool/solution, especially considering the fact that e-commerce sales can support small and medium businesses that form the backbone for certain economies. This is expected to substantially spur the growth of digital payment methods across various economies.”

According to Mordor, other drivers of the growth trend in digital payments include:

  • Greater convenience, favorable government policies and evolving consumer behavior worldwide
  • Rapid rise in smartphone penetration throughout emerging economies
  • Introduction of mobile wallets across the world
  • Widespread adoption of retail digital payment services across the vast population of China, serving as a kind of test case for other countries

Management Team

Ben Errez, Chairman of the Board of Directors

Ben Errez’s past positions have included positions at large companies like Microsoft and Intel. He has brought this expertise to lead GreenBox into the forefront of the blockchain-based financial software, services, and hardware market.

Mr. Errez was one of the early managers of Microsoft in 1991. From 1991 to 2004, he served as Software Development Lead for the Microsoft International Office Group. He led the International Microsoft Office Components team (Word, Excel, PowerPoint) in design, engineering, development, and successful deployment. He also served as Executive Representative of Microsoft Office and was a founding member of the Microsoft Trustworthy Computing Team both within the company and internationally. Mr. Errez co-authored the first Microsoft Trustworthy Computing Paper on Reliability. At Microsoft, he was responsible for the development of the first Microsoft software translation Software Development Kit (“SDK”) in Hebrew, Arabic, Thai, and Simplified Chinese, as well as the development of the first bidirectional extensions to Rich Text Format (“RTF”) file format and all bidirectional extensions in text converters for Microsoft Office. He also contributed to the development of the international extensions to the Unicode standard to include bidirectional requirements under the World Wide Web Consortium (“W3C”).

In 2004, Mr. Errez transitioned into the world of consulting, where he held the position of Principal Consultant from founding to the present date, through which he advises clients in the South Pacific region with market capitalizations ranging from $50 million to $150 million on commerce, security, reliability, and privacy.

In 2017, immediately before partnering with Fredi Nisan to launch GreenBox, Mr. Errez was asked to take over the Microsoft Alumni Network for the Southern California region as a regional director. Mr. Errez has been a principal of GreenBox since its inception in 2017.

Fredi Nisan, Chief Executive Officer

Fredi Nisan’s career in technology began during his years of service in the Israeli Defense Forces, where he served as IT Manager for all of Israel’s Northern Bases. After serving in the military, Mr. Nisan opened and operated a computer hardware store before becoming the Inventory Operations Manager for Zicon Israel in 2005, a hardware and software producer. At Zicon, he supervised inventory operations, worked on quality controls for motherboards and chips, and educated customers on software and hardware product functionality. Subsequently, Mr. Nisan moved to the United States, where he worked for One Coach in San Diego, California, as a business coach. One Coach specializes in customized growth solutions for small business owners, including the latest strategies for sales, internet marketing, branding, and ROI. Mr. Nisan was consistently ranked as the top salesperson for small business coaching while working with One Coach.

In 2010, Mr. Nisan launched Brava POS, where he served as President until 2015. Brava POS provided point of sale (“POS”) systems for specialty retail companies. Mr. Nisan developed software to provide clients with solutions for issues ranging from inventory management to payroll to processing high volume transactions in the form of a cloud-based POS system. This system had the capability to manage multiple stores with centralized inventory and process sales without an internet connection, and offered a secure login for each employee, as well as including advanced inventory management and reporting, plus powerful functionality for its end users.

In 2016, Mr. Nisan founded Firmness, LLC. Through Firmness, he created “QuickCitizen,” a software program that simplifies the onboarding process for new clients of law firms specializing in immigration issues. The QuickCitizen software significantly reduced law firms onboarding processing time from more than three hours to approximately 15 minutes. Mr. Nisan has been a principal of GreenBox since its August 2017 inception. In January 2018, Firmness sold QuickCitizen to GreenBox.

Jacquline B. Reynolds, Chief Marketing Officer

Jacqueline B. Reynolds is the company’s Chief Marketing Officer. She served most recently as vice president of marketing for Sprouts Farmers Market. She has built her reputation as a world-class global marketer, working with Coca-Cola, McDonald’s, Verizon, Walmart, L’Oréal, Xbox, 7-Eleven and many other Fortune 500 brands. She has managed award-winning marketing programs with partners such as the NFL, Super Bowl LIV, the Olympics, the FIFA World Cup, Sony Pictures, Universal Music and others.

GreenBox POS (NASDAQ: GBOX), closed Wednesday's trading session at $3.66, up 3.0986%, on 246,211 volume. The average volume for the last 3 months is 246,211 and the stock's 52-week low/high is $2.24/$19.1598.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

The cannabis edibles segment has slowly been gaining popularity over the years, eventually generating $1.28 billion in sales in 2021. Cannabis companies have done this by incorporating cannabinoids such as THC and CBD into a wide variety of foodstuffs. However, one segment marijuana companies have had trouble breaking into is sugar-free foods. As people become more aware of the long-term effects of heavy sugar consumption, a growing percentage of the population is being drawn towards low-sugar alternatives. But with cannabis slowly shedding the “stoner” image and becoming more of a wellness product, TribeTokes CEO Degelis Tufts Pilla says cannabis companies can take advantage of this growing segment. As the product offerings of entities such as Flora Growth Corp. (NASDAQ: FLGC) continue evolving, there is likely to be no limit to the applications to which marijuana and its different compounds will be put.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $1.75, up 6.0606%, on 267,598 volume. The average volume for the last 3 months is 267,598 and the stock's 52-week low/high is $1.31/$21.45.

Recent News

Hollywall Entertainment Inc. (OTC: HWAL)

The QualityStocks Daily Newsletter would like to spotlight Hollywall Entertainment Inc. (OTC: HWAL).

Hollywall Entertainment (OTC: HWAL), an innovative telecommunication and broadcasting company, is focused on ensuring “digital equity” through access to the internet and its resources. “Hollywall president and CEO Darnell Sutton helped to pioneer the concept of ‘Fiber to the People’ as a way of empowering small communities, especially those in the South’s ‘Black Belt,’ to pursue the self-determination so central to American ideals. Hollywall’s HW Vision subsidiary is offering affordable high-speed internet access, telehealth, energy, web conferencing, domain and hosting, IoT, managed internet services, video broadcasting, and nationwide unlimited talk, text and data cellular phone plans to its customers,” a recent article reads. “Hollywall derives its revenue from an extensive catalog of music, film, television, software, and game library rights, and has announced the pending development of non-fungible tokens (‘NFTs’) based on its rights to artists’ works.” To view the full article, visit

Hollywall Entertainment Inc. (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts.

Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City.

Hollywall Entertainment Inc. (Hollywall) Subsidiaries

Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment.

Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader.

HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide.

Hollywall Development Company (“HWDC”)

HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments.

HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities.

HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more.

HW Vision and Omnipoint Technology Inc.

Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

  • 5G and Fiber Network installation services
  • Affordable high-speed internet access
  • Telehealth services
  • Domain hosting
  • Web conferencing
  • Managed internet services
  • Nationwide unlimited talk, text and data cellphone plans
  • Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021.

Hollywall Entertainment Digital Music Network and Hollywall TV

The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry.

Market Outlook

Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries.

The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (

Management Team

Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management.

Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few.

“Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine.

“After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release.

Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others.

Hollywall Entertainment Inc. (OTC: HWAL), closed Wednesday's trading session at $1.05, up 191.6667%, on 82,665 volume. The average volume for the last 3 months is 82,665 and the stock's 52-week low/high is $0.33/$2.519.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar dose profile and onset of effect to IV DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability,” said Doug Drysdale, chief executive officer of Cybin. “CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic. As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians.” To view the full press release, visit New research has found that during primary care visits, screening for unhealthy consumption of alcohol by patients through the use of a validated questionnaire is rarely done. This is despite the current recommendations provided by the U.S. Preventive Services Task Force. Figures show that between 2014 and 2016, screening was performed during only about 3% of office visits. The researchers recommend that alcohol screening rates be increased through the use of technology-based screening strategies in addition to making use of the cutting-edge alcohol use disorder treatments being developed by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) in order to forestall the complications that result from unhealthy alcohol consumption.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.8066, up 12.0278%, on 875,736 volume. The average volume for the last 3 months is 858,193 and the stock's 52-week low/high is $0.70/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

  • Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”)
  • CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA 
  • CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months
  • CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there
  • The study will evaluate more than 200 patients worldwide who have had a recurrence of tumor progression following standard first line therapy
  • The company expects interim results from the study in 2023 after 30 to 50 percent of the total expected patients have reached the six-month point, with a primary completion date in October 2024 and ultimate resolution in February 2025

Biopharmaceutical cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is reporting new advances in its rollout of a global clinical trial the company describes as “potentially pivotal” in producing a treatment for an aggressive brain cancer. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $0.43, up 7.5%, on 3,011,382 volume. The average volume for the last 3 months is 2.801M and the stock's 52-week low/high is $0.2453/$2.68.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SPYR Inc. (OTCQB: SPYR).

SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company and its subsidiary, Applied Magix Inc., are evaluating the potential for entering the mobile virtual network operators (“MVNO”) market by offering special mobile phone plans designed exclusively for iPhone users. Applied Magix develops and resells Apple(R) ecosystem-compatible products in the growing multibillion-dollar IoT smart-home and connected-car markets. The MVNO space has seen dramatic growth within the mobile phone space by offering more affordable plans. Because MVNOs don’t have their own wireless networks, they typically use another carrier’s platform to provide coverage. Applied Magix is exploring that possibility with various existing relationships. “There are a lot of great carriers out there providing mobile services, but for most of them it feels like their Apple customers are an afterthought, which is frustrating if you’re an Apple user,” said Applied Magix CEO Dr. Harald Zink in the press release. “We feel that we can do better. Of course, we are not just going to jump into this. We are carefully exploring and evaluating the available MVNO offerings, as well as exploring and evaluating the market space, to see what customers want.” To view the full press release, visit

SPYR Inc. (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc. subsidiary, develops and resells Apple®-ecosystem-compatible products with an emphasis on the growing, multibillion-dollar Internet of Things (IoT) Smart Home and Connected Car markets.

SPYR continues to identify and target acquisitions with an aim of growing its footprint in the industry and expanding the products it offers consumers, including companies developing artificial intelligence and smart-technology products. In 2020, SPYR acquired Applied MagiX Inc., a registered Apple developer and reseller of Apple ecosystem compatible products with an emphasis on the smart home market, as a wholly owned subsidiary. Applied MagiX operates in the IoT market and, more specifically, the segment of the market related to the development, manufacture and sale of devices and accessories specifically built on Apple’s HomeKit® framework. These products work within the Apple HomeKit ecosystem and are exclusive to the Apple market and its consumers.

Initially, while working to develop, manufacture and sell its own line of branded products, Applied MagiX will be sourcing HomeKit products and accessories from worldwide manufacturers, vetting and selecting best-of-breed products, selling them directly to consumers and supporting them. The company focuses on Apple consumers – a target market with higher disposable income and a demonstrated willingness to pay a premium for quality products. On average, Apple product users spend roughly twice as much on technology as other smartphone users. Those who purchase smart home products spend more than $3,000 on average.

By creating smart hardware and software solutions exclusively for Apple consumers, SPYR addresses a problem faced by that market – having few “smart” devices that integrate with Apple’s HomeKit, despite being the most affluent and loyal consumers of tech products.


The company’s Applied MagiX subsidiary offers multiple product lines to its target markets. First, the subsidiary is a reseller of third-party manufactured Apple HomeKit and Apple CarPlay compatible products. HomeKit comes pre-installed on every new iPhone, while the CarPlay platform is licensed by all major auto manufacturers. Applied MagiX identifies white label products, applies the company’s branding, improves the software and sells these improved products to consumers. Finally, Applied MagiX is developing its own proprietary line of smart home and connected car products, including Apple-compatible home cameras, sensors and alarms, as well as additional Apple-compatible smart car products in the iOS ecosystem.

Among the subsidiary’s products sold to consumers are:

  • The MagixDrive Wireless CarPlay adapter, which allows users to access CarPlay wirelessly using their iPhones
  • The HomeKit Secure Video Camera with iCloud Storage
  • The Multipurpose Sensor with Alarm
  • The Environment and Motion Sensor
  • The Window and Door Contact Sensor

Market Outlook

According to Statista, the global smart home market is expected to generate revenue of more than $104 billion in 2021. The market is forecast to hit more than $187 billion in revenue by 2025, recording a CAGR of 15.75 percent.

The number of active households in the worldwide smart home market is expected to reach nearly 500 million by 2025. Household penetration is just over 12 percent in 2021 and is projected to nearly double by 2025 to more than 22 percent.

Allied Market Research valued the global connected car market at more than $63 billion in 2019 and projected a CAGR of 17.1 percent, which would push revenue to more than $225 billion by 2027. Allied identified rising consumer demand for connectivity solutions, surging need for constant connectivity, increasing dependency on technology and an upsurge in tech-savvy population as key factors driving the projected growth of the connected car market.

Management Team

James R. Thompson is the CEO, President and General Counsel of SPYR. Over the past 28 years, Mr. Thompson has deftly managed a colorful spectrum of legal clients and situations. In the process, he has helped many companies – both large and small – thrive. Now he welcomes the challenge to take the company and his career in an entirely new direction. A native of Philadelphia, he holds a J.D. from Rutgers University and a Bachelor of Science from the University of Denver.

Jennifer Duettra is the Executive Vice President of SPYR. She brings a great deal of knowledge in mobile gaming and pop culture to the company. She is an attorney and was thrilled by the prospect to combine her law experience with a chance to be creative. She is a native of Colorado and received her Bachelor of Arts in Political Science and Speech Communication from Colorado State University. She holds a J.D. from Harvard University.

Trang Nguyen is the CFO of SPYR. From 2019 to 2020, she served as the Financial Reporting Manager for Del Taco, where she was responsible for the preparation and filing of periodic financial reports with the U.S. Securities and Exchange Commission. From 2016 through 2019, Ms. Nguyen was Accounting Manager for Pinnacle Tax Accounting in Los Angeles, California. She was a part of Ernst & Young’s audit team in Los Angeles from 2006 to 2008, leading engagements on interim and year-end ad SOX 404 auditing procedures for major enterprise accounts. Ms. Nguyen holds a Bachelor of Art, Business Economics (Minor in Accounting) from the University of California, Los Angeles. She is a certified public accountant with an inactive license.

Dr. Harald Zink is the CEO, Founder and Chief Product Architect of SPYR subsidiary Applied MagiX. Prior to founding Applied MagiX, he was Director of Technologies and later Vice President of Technologies at Sarkissian Productions in Los Angeles. He also served as Director of Technologies at SMZ Technologies and, for more than 17 years, as Macintosh Technology Consultant to The Walt Disney Studios in Burbank, California. He speaks five languages and holds degrees from the University of California, Riverside.

Kelly Clark is the COO of Applied MagiX. Before joining the subsidiary, he worked as Vice President of Sales Operations at TruClear Global. Prior to that, Mr. Clark was Senior Director of Program Management at Pacific Group Ventures and Operations Manager at Barco. He has also held operations management positions at Deluxe Digital Studios and Sony Pictures Entertainment. Mr. Clark holds a bachelor’s degree in international business from the University of Southern California.

SPYR Inc. (OTCQB: SPYR), closed Wednesday's trading session at $0.0724, up 25.913%, on 1,902,874 volume. The average volume for the last 3 months is 1.903M and the stock's 52-week low/high is $0.02355/$0.19.

Recent News

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

American Cannabis Partners (“ACP”) is expected to see increasing opportunities to market its products as the cannabis landscape continues to shift, with growing numbers of states allowing some form of the substance and federal legislation examining changes in legal status. A recent article, which contains excerpts from a Hemp Industry Daily (“HID”) piece that looked at cannabis marketing trends for this year, documents that while Google is cracking down on advertising cannabis, other platforms like Twitter, Reddit and Quora are opening up. The article reads: “‘Of all the social media platforms, we have our eyes set on streaming platforms like Discord and Twitch in 2022. In a recent study by the Brightfield Group, up to 54% of video gamers consume cannabis while gaming.’ The [HID] article observed that Twitch has already begun to see growth as it allows cannabis-related content as long as the substance is legal in the state or country from which the stream originates, and the message doesn’t attempt to sell cannabis. ‘With 140 million active users, we wouldn’t be surprised to see more cannabis brands partner with Twitch streamers,’ the article stated. These look-ahead evaluations are helpful for American Cannabis Partners, which is a fully licensed, large-scale, 100% organic cannabis cultivation company.” To view the full article, visit

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News


Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

  • Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1
  • SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant
  • Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far, the company has explored MDMA, LSD, DMT, mescaline, 2C-B, and psilocybin mushrooms ( Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The exemption also allows the lab to obtain psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. The company anticipates moving forward and developing innovative analytical methods for psychedelic research. According to the announcement, the lab has also submitted an application for a dealer’s license with the intent of commercializing psilocybin research and associated intellectual property (“IP”) for medical and research purposes. "Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds," said Delic Labs cofounder Dr. Markus Roggen in the press release. “Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer's license is secured.” To view the full press release, visit A new study has found that psilocybin causes temporary changes to the basic structural organization of normal sleep in lab mice. Professor Vladyslav V. Vyazovskiy of the University of Oxford, who conducted the study, stated that evidence had shown that psychedelics such as psilocybin could rapidly reduce core symptoms of various psychiatric conditions, even in serious cases that were resistant to other treatments. The researchers’ objective was to examine the potential impact that psilocybin had on sleep, as sleep disturbance contributed to the continuation as well as the onset of diverse mental illnesses. For their study, the researchers used animal models to better understand the mechanisms that underlie the effects which psilocybin has on sleep. They implanted electrodes in mice before administering psilocin, which is a psilocybin metabolite, and monitoring their patterns of sleep. There is a lot more that the world has yet to learn about various psychedelic compounds, and that is why the R&D activities and programs of sector players such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) need all the support they can get.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Wednesday's trading session at $0.035, off by 2.7778%, on 404,192 volume. The average volume for the last 3 months is 404,192 and the stock's 52-week low/high is $0.03308/$0.398.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

  • TripAdvisor’s annual roundup of top destinations shows travelers returning to normalcy
  • SHRG’s Hapi Travel Destinations focuses on offering discounted destinations with a maximized experience
  • Company differentiates itself by offering unfettered access to tremendous savings, exclusive benefits on a level never before seen

Despite the global pandemic still impacting life in many ways, most indicators show that travel is picking back up. This is good news for Sharing Services Global (OTCQB: SHRG) and its new direct-selling travel division, which offers exclusive benefits and first-class discount travel opportunities. 

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed Wednesday's trading session at $0.0311, off by 12.8852%, on 10,400 volume. The average volume for the last 3 months is 10,400 and the stock's 52-week low/high is $0.03/$0.25.

Recent News

Laredo Oil Inc. (OTC: LRDC)

The QualityStocks Daily Newsletter would like to spotlight Laredo Oil Inc. (LRDC).

Laredo Oil Inc. (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (EOR) methods.

Laredo Oil is headquartered in Austin, Texas.

Conventional Acreage

Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties.

The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities.

The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods.


In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage™ (UGD) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics.

Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected.

Market Outlook

The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand.

Management Team

Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers.

Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida.

Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University.

Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University.


This press release and the statements made by Laredo Oil, Inc. in this press release may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements describe Laredo Oil’s future plans, projections, strategies and expectations, and may be identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or the negative versions of those words or other words of similar meaning. These forward-looking statements are based on assumptions and involve a number of risks, uncertainties, situations and other factors that may cause the actual results, level of activity, performance or achievements of Laredo Oil or the oil industry to be materially different from any future results, level of activity, performance or achievements expressed or implied by these statements. These factors include changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in the reports filed with, or furnished to, the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Laredo Oil undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Laredo Oil Inc. (LRDC), closed Wednesday's trading session at $0.12, up 20%, on 1,730 volume. The average volume for the last 3 months is 1,730 and the stock's 52-week low/high is $0.0401/$0.2714.

Recent News

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF)

The QualityStocks Daily Newsletter would like to spotlight DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF).

DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals.

The company offers financial, business, and human capital AI predictive solutions to businesses, institutions, and consumers to improve decision-making.

The DigiMax core solutions are:

  1. CryptoHawk AI – CryptoHawk is a deep learning AI solution (SaaS) that monitors and analyzes live select cryptocurrencies and financial markets. The CryptoHawk AI solution is offered to retail clients as a monthly subscription. Generated data provides subscribers with price trend predictions for better investment strategies.
  2. Cryptocurrency Hedge Fund – A long/short cryptocurrency hedge fund for high net worth, institutional, and family office clients was launched on September 1, 2021. The company’s crypto hedge fund earns clients’ management and overall performance fees.
  3. Projected Personality Interpreter (PPI) – DigiMax solutions utilize AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services by measuring and correlating personal attributes.
  4. Navee Predict – DigiMax data scientists provide companies with the unprecedented power of enhancing decision-making by analyzing, detecting changes and forecasting patterns.

The company’s team has extensive experience in finance, trading, machine learning (ML), neural language processing, AI, big data, and cryptocurrency technology. DigiMax leverages AI and its expert team to translate data into actionable predictive insights across the financial, business, and human dimensions, enhancing the decision-making capacity of organizations. DigiMax is an official IBM Watson partner with more than 30 years in data science and artificial intelligence.


Business and Financial Capital Solutions

CryptoHawk AI is a cryptocurrency price and trend prediction solution offered as a web application ( and a mobile application by the end of 2021. The value for the user is to capture gains and take advantage of volatility while reducing risk and engaging in smarter and simpler trading.

The key features:

  • Trend Prediction Indicator (“TPI”)
    The TPI is a superior model that leverages the cryptocurrencies analyzed by the AI and other market-driven data and policies to produce actionable predictions in the form of:
    • Prediction cards
    • Cryptocurrency graphs with optional market indicators
    • Email/SMS alerts
  • Trend Watch
    Trend Watch is a one-week look ahead machine learning prediction for a select portfolio of mature cryptocurrencies. Trend Watch predicts a trend being UP or DOWN and provides a price target. Users have access to:
    • A list of select cryptocurrencies with predictive graphs

The system alerts investors through email and text messages when a price trend changes, allowing users to act confidently.

Cryptocurrency Hedge Fund

On September 1, 2021, DigiMax launched its Cryptocurrency Hedge Fund to offer high net worth, institutional, and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms. The official launch is expected in the coming months.

The fund is led by 40-year hedge fund veteran Ian Hamilton and has an experienced investment and fund management team. This actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies.

AI Business Prediction as a Service

The company offers predictive insights to businesses through automation and its innovative and proprietary AI and ML technology. Traditional models are expensive, because they are created and developed by data scientists dedicated to solving specific business questions that require costly customization and weeks, if not months, of development. With DigiMax, companies have access to solutions and services at a fraction of the price of traditional and experimental approaches. By combining AI with ML prediction technology, the company delivers insights on:

  • Sales forecasts
  • Optimal inventory levels
  • Supply chain management
  • Invoice payment projections
  • Targeted segmentation for marketing campaigns

Human Capital Solutions

AI-Powered Projected Personality Interpreter

The Projected Personality Interpreter (“PPI”) evaluates and improves customers’ workforce, brand and culture by revealing the personality traits and sentiment buried in human expression. The PPI empowers organizations with comparative insight for better hiring decisions, reducing employment attrition and improving workplace culture.

PPI provides a comprehensive and complete solution, offering:

  • Recruitment campaign management
  • Custom questionnaires, desirable traits recipes, and group likenesses
  • Detailed personality reports to compare and contrast peers
  • API for advanced integration with alternative systems of record

DigiMax leverages IBM Watson and a custom algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, providing hiring managers with a comprehensive report that improves decision making and takes the bias out of the process. The company’s solution is currently in use by 17 law enforcement agencies in North America and is used across the 10 global recruitment brands of Shepherd Search Group.

Market Overview

The AI industry has a five-year CAGR of 18.4%, with revenues projected to reach $37.9 billion by 2024. Some more optimistic forecasts have the market worth as much as $15 trillion by 2030. It’s estimated that 80% of all emerging technologies in 2021 have AI foundations. About 40% of all businesses use AI in their operations. According to Industry Ark, artificial intelligence use in the recruitment market was valued at $580 million in 2019.

Management Team

Chris Carl, CEO

Chris Carl has over 20 years of experience as a public-company CEO and has built several successful businesses across multiple categories. He has a proven ability to lead and has a track record of execution, revenue growth, and value creation.

Thierry Hubert, CTO

Thierry Hubert has 30 years of technology experience with Fortune 100 companies worldwide and is an early pioneer in applying artificial intelligence to solve big data and unstructured information challenges with IBM as a Director of R&D in emerging technology, knowledge management, and process innovation. He has received awards, recognitions, and grants that contributed to his ongoing collaboration with industry leaders.

David Bhumgara, CFO

David Bhumgara is a senior finance executive with over 25 years of leadership experience and proven expertise in finance, financial reporting, accounting, corporate finance, budgeting, financial modeling, and mergers & acquisitions.

Damon Stone, Trading Strategy Advisor

Damon Stone is an experienced stock and crypto trader who works very closely with the data science team as a subject matter expert. During 15 years at Merrill Lynch as a market maker and proprietary trader, he traded many different sectors, culminating in heading up a $250 million trading desk.

Ross Power, Senior Innovation Engineer
Ross Power is an experienced technical system architect with a demonstrated history of working on advanced technologies, including AI algorithms, IoT solutions, 3D printing, Innovation in BCI (Brain-Computer Interfacing), and RC flight and navigation systems.

DigiMax Global Inc. (DBKSF), closed Wednesday's trading session at $0.04, even for the day, on 267,044 volume. The average volume for the last 3 months is 267,044 and the stock's 52-week low/high is $0.021/$0.27.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.